Clinical Trials Logo

Smokers clinical trials

View clinical trials related to Smokers.

Filter by:

NCT ID: NCT01213706 Completed - Asthma Clinical Trials

Effect of Whole Body Periodic Acceleration on Airway Endothelial Function

Start date: October 2009
Phase: N/A
Study type: Interventional

In the present proposal the investigators wish to assess the effect of a single session with the device known as Exer-Rest® which applies Whole Body Periodic Acceleration (WBPA) on baseline airway blood flow (Qaw) and in Qaw variation, in current smokers, glucocorticoid-naïve asthmatics, and age-matched healthy never-smokers, with the expectation that the treatment will transiently increase the Qaw, and to a greater extent in the current smokers and patients with asthma who have endothelial dysfunction.

NCT ID: NCT01182129 Completed - Healthy Subjects Clinical Trials

4 mg Nicotine Polacrilex Gum and Swedish Portion Snus

SMWS06
Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Fifteen healthy smokers are given single doses of General Onyx 1 g portion snus and General White 1g portion snus, respectively, and one piece of Nicorette 4 mg chewing gum. Serial blood samples are drawn before (0), 2, 4, 8, 16, 24, 30, 45, 60 minutes, 1.5, 2, 4, 6 and 8 hours after administration for determination of nicotine. Mean + SD extracted dose of nicotine from each preparation will be estimated. The percentage extracted of the nicotine content will be calculated. Cmax and Tmax will be estimated. A comparison to Nicorette 4 mg chewing gum will be made. The dose absorbed into the systemic blood circulation (AUC) in relation to the dose following the 4 mg Nicorette chewing gum will be calculated. Self-reports of subjective effects will be obtained up to 30 minutes after the test product is administered using a 100 mm visual analogue scale (VAS) anchored with "not at all" to "extremely". Study hypothesis is that Cmax and AUC of Nicorette 4 mg chewing gum and Swedish snus are similar.

NCT ID: NCT00918073 Completed - HIV Infections Clinical Trials

Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Patients

Start date: November 2007
Phase: N/A
Study type: Observational

We will conduct a sub-study of "An Innovative Telephone Intervention for HIV+ Smokers," (NCT00502827) conducted by Drs. Gritz, Vidrine, and others. This is a randomized, prospective trial that will evaluate a cellular phone delivered counseling intervention versus standard of care for smoking cessation. In our sub-study, we will evaluate rates of progression in atherosclerosis in HIV/AIDS patients who quit smoking versus those who continue smoking by measuring carotid intima-media thickness(CIMT) and biomarkers of atherosclerosis at time point baseline, 1 year, and 3 year. The biomarkers measured include high-sensitivity Creactive protein, homocysteine, and IL-6. We will also evaluate rates of progression of CIMT in those who quit smoking versus those who continue smoking, based on race, sex, state of HIV disease, comorbid diseases, and lipid profile.

NCT ID: NCT00781599 Completed - Smokers Clinical Trials

Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers

Start date: October 2008
Phase: N/A
Study type: Interventional

Little is known about the support needed to improve compliance with Chantix for smoking cessation. This is a two arm pilot study of African American smokers to provide varying levels of side effect management and compliance support during a 12 week treatment period. The primary aim of the study is to estimate the effect of induction support compared to standard care in increasing compliance with Chantix at month 3

NCT ID: NCT00736047 Completed - Smokers Clinical Trials

Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

Start date: August 2008
Phase: Phase 2
Study type: Interventional

This study is designed to determine the efficacy of high nicotine-specific antibody titers in smoking cessation.

NCT ID: NCT00483015 Completed - Smokers Clinical Trials

Differences in the Presentation Outcome and Response to Treatment Between Never- Smokers and Smokers With NSCLC

Start date: March 2006
Phase: N/A
Study type: Observational

We wish to discover if there is a difference in the presentation, response to treatment and survival of never- smokers with lung cancer as compared to ever- smokers. We also plan to obtain tumor specimens to compare the genetic and proteomic expression between smokers and never smokers

NCT ID: NCT00369616 Completed - Smokers Clinical Trials

Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers

Start date: December 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to help smokers quitting by vaccinating them with CYT002-NicQb. Upon vaccination, the smoker will generate antibodies directed against free nicotine. The antibodies will bind nicotine and prevent its passage into the brain. The successfully vaccinated smoker will have no reward effect after smoking, thus braking the vicious circle of nicotine addiction.

NCT ID: NCT00341640 Completed - Pregnancy Clinical Trials

Metabolism of Nicotine and Cotinine in Pregnant African-American Women

Start date: January 6, 2005
Phase: Phase 1
Study type: Interventional

This study will provide information regarding the optimal dose and duration of nicotine replacement using the nicotine patch for a smoking cessation study of pregnant African-American women. Previous studies have shown that pregnancy, race and ethnicity can affect the way people metabolize nicotine. The information from this study may help scientists develop ways to help pregnant African-American women quit smoking and not start smoking again after delivery. African-American women 18-30years of age who are in the second trimester of a healthy pregnancy, who are carrying only one baby and who smoke 10 or more cigarettes a day may be eligible for this study. Candidates are screened with a medical history, physical examination and urine test. They receive counseling to help them quit smoking. Those who cannot quit smoking within 7 to 10 days after receiving counseling may be invited to join the study. Participants are admitted to a private room in the Pediatric Clinical Research Center at Children's National Medical Center in Washington, D.C., for 48 hours, during which time they are not permitted to smoke. After a "wash out" period, a nicotine patch will be applied according to these doses and schedules: - 21 mg patch for 24 hours - 21 mg patch for 16 hours - 14 mg patch for 24 hours - 14 mg patch for 16 hours An intravenous (IV) line is placed in the subject's arm and 12 blood samples are drawn through the line at intervals during the 48 hours. Twleve urine and saliva samples are also collected. Blood, urine, and saliva samples are analyzed for nicotine and cotinine (a product of nicotine metabolism) levels, and DNA will be collected studied for genes that are associated with nicotine and cotinine metabolism. Participants are interviewed about their urges to smoke, quality of sleep, etc.

NCT ID: NCT00320697 Completed - Schizophrenia Clinical Trials

Smoking Relapse Prevention in Schizophrenia

Start date: April 2006
Phase: Phase 4
Study type: Interventional

This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.